Here's How D-Wave Quantum's Commercial Momentum Is Gaining Strength

D-Wave (QBTS) kept Q2’26 revenue essentially flat at $3.1M, but commercial mix improved sharply (62.4% of revenue vs. 45.1% YoY). QCaaS subscription revenue rose 50% to $1.9M, with first-half bookings up 1,120% including a $20M annealing system sale to Florida Atlantic University; remaining performance obligations jumped 668% to $40.7M, with ~57% expected to be recognized in the next 12 months. Despite this momentum, the stock is still flagged with an expensive valuation (forward P/S 90.6x vs. industry 3.97x) and a Zacks Rank of #4 (Sell), while the 2026 loss-per-share estimate moved to 29 cents.

Analysis

The investable signal here is not that quantum revenue is “real” — it is that customers are starting to buy time, not just demos. That favors the vendors whose mix shifts toward recurring QCaaS and repeat enterprise use, but it does not automatically justify the current multiple: at ~90x sales, QBTS needs gross-margin dollars and retention, not just backlog optics, to avoid a classic pre-profitability compression.

Second-order, the whole cohort gets judged against conversion quality. If QBTS can turn backlog into recognized revenue within the next 4 quarters, it forces QUBT and RGTI to show similarly durable demand, but if conversion slips the market will likely punish the entire basket as “grant/experiment” capital rather than commercial adoption. The near-term risk is that system sales and pilot bookings are lumpy while estimates keep drifting lower; that is a setup where revenue beats can coexist with multiple contraction.

Contrarian view: consensus is likely over-reading “commercial momentum” as a structural break. The better question is whether quantum buyers are committing to workflows or simply spending small budgets on optionality; if it is the latter, the revenue base remains too small to defend premium valuations. RGTI is the cleaner relative beneficiary because the market can underwrite a more tangible funding/capex path, while QBTS carries the highest bar for sustaining a premium multiple if next-quarter growth normalizes.

Key Decisions for Investors

• Short QBTS into strength over the next 1-3 weeks; risk/reward favors multiple compression if the market focuses on the 90x sales valuation and downward 2026 EPS revisions rather than backlog headlines.
• Pair trade: long RGTI / short QBTS for 1-3 months. RGTI has the cleaner catalyst stack, while QBTS is more exposed to a rerating lower if conversion and margin quality do not improve.
• If already long the quantum basket, rotate from QBTS into QUBT or RGTI on rallies; treat QBTS as the lowest-quality exposure until at least two consecutive quarters show backlog-to-revenue conversion and estimate stabilization.
• Set a watch item on QBTS 12-month RPO conversion and subscription mix at the next two prints. Falsifier for the bearish view: sustained >30% sequential backlog conversion or a material upward revision to 2026 revenue/EBITDA expectations.